title: Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.
authors.affiliation: Battelle Medical Technology and Policy Research Center, Washington, D.C. 20024.
authors.forename: D A
authors.initials: DA
authors.lastname: Revicki
authors.forename: B R
authors.initials: BR
authors.lastname: Luce
authors.forename: J M
authors.initials: JM
authors.lastname: Weschler
authors.forename: R E
authors.initials: RE
authors.lastname: Brown
authors.forename: M A
authors.initials: MA
authors.lastname: Adler
mesh_terms: D000328:Adult; D000359:Aftercare / Q000191:economics; D002908:Chronic Disease; D003024:Clozapine / Q000627:therapeutic use*; D003156:Community Mental Health Services / Q000191:economics; D003362:Cost-Benefit Analysis; D003984:Dibenzazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007902:Length of Stay / Q000191:economics; D008297:Male; D011569:Psychiatric Status Rating Scales; D012017:Referral and Consultation / Q000191:economics; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics; D012565:Schizophrenic Psychology
chemical_list: D003984:Dibenzazepines; D003024:Clozapine